Loading clinical trials...
Loading clinical trials...
A Phase IV, Multicentre, Open Label, Single Group Exploratory Study to Assess the Clinical Value of Enumeration of Circulating Tumour Cells (CTCs) to Predict Clinical Symptomatic Response and Progression Free Survival in Patients Receiving Deep Subcutaneous Administrations of Somatuline® (Lanreotide) Autogel® to Treat the Symptoms of Functioning Midgut NeuroEndocrine Tumours (NET)
Conditions
Interventions
lanreotide acetate
Locations
14
United Kingdom
Basingstoke & North Hampshire Hospital
Basingstoke, United Kingdom
Queen Elizabeth Hospital
Birmingham, United Kingdom
University Hospital Wales
Cardiff, United Kingdom
Beatson West of Scotland Cancer Centre
Glasgow, United Kingdom
St James's University Hospital
Leeds, United Kingdom
University Hospital Aintree
Liverpool, United Kingdom
Start Date
May 1, 2014
Primary Completion Date
June 1, 2017
Completion Date
June 1, 2017
Last Updated
June 7, 2019
NCT04579679
NCT04649580
NCT02788565
NCT03592940
Lead Sponsor
Ipsen
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions